Sudarshan Pharma raises $20M through foreign convertible bonds
What's the deal? Indian pharmaceutical company Sudarshan Pharma Industries has issued $20M in foreign currency convertible bonds (FCCBs), with Mumbai-based law firm Rajani Associates advising on the transaction.
FCCBs are debt instruments issued in a foreign currency that can be converted into equity shares of the issuing company. They allow Indian firms to raise capital from international investors without immediately diluting existing shareholders.
Why now? Indian pharmaceutical companies have been tapping international capital markets as the sector expands. FCCBs offer a way to access foreign funds at potentially lower interest rates while giving investors an equity upside.
The signal: The deal reflects continued international investor appetite for Indian pharma. As the country's pharmaceutical industry grows — both in domestic production and global exports — companies like Sudarshan Pharma are using cross-border financial instruments to fund their next phase of growth.
Read more: barandbench.com
